Serina Therapeutics, INC Form 4 insider transactions

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold a total of 6,500 common shares in early December 2025 after exercising stock options, pursuant to a Rule 10b5-1 plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 5,965 shares of common stock.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 535 common shares for a profit under a Rule 10b5-1 plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised options and sold 6,500 shares of common stock for a profit.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock.

Serina Therapeutics director Stephen K. Brannan was granted 10,000 stock options with an exercise price of $3.91.

Serina Therapeutics Director Gregory Bailey acquired 10,000 stock options with an exercise price of $3.91, vesting based on service or the next annual meeting.

Serina Therapeutics Director Richard Peter Marshall acquired 10,000 stock options with an exercise price of $3.91, vesting based on service or the next annual meeting.

Serina Therapeutics Director Jay Venkatesan was granted 10,000 stock options with an exercise price of $3.91, vesting over one year.

Serina Therapeutics director Karen J. Wilson was granted 10,000 stock options with an exercise price of $3.91, vesting over one year.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned sale of 3,398 common shares after exercising stock options.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 3,102 shares of common stock after exercising options.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned sale of 5,551 common shares after exercising stock options.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 949 shares of common stock after exercising options under a pre-arranged trading plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock for approximately $4.97 per share.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 4,326 shares of common stock under a Rule 10b5-1 plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 47,674 shares of common stock for a total of approximately $328,613.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, reported exercises of stock options and subsequent sales of common stock under a Rule 10b5-1 plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold 5,500 shares for a weighted average price of $5.25 per share.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned sale of 5,500 common shares after exercising stock options.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold the acquired common stock under a pre-arranged 10b5-1 plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold the acquired common stock in a pre-planned transaction.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock for a significant gain in a pre-planned transaction.

Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold the acquired common stock.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock for a significant gain as part of a pre-arranged trading plan.

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned transaction, exercising stock options and subsequently selling 6,500 shares of common stock.

Serina Therapeutics, Inc. Director Stephen K. Brannan was granted 40,000 stock options with an exercise price of $5.89, vesting over three years, as disclosed in a recent SEC Form 4 filing.

Jay Venkatesan, a director of Serina Therapeutics, acquired Series A Convertible Preferred Stock on April 8, 2025.

Gregory Bailey, a director of Serina Therapeutics, acquired 762,548 shares of Series A Convertible Preferred Stock on April 8, 2025.

Steven Ledger, CEO of Serina Therapeutics, acquired 95,730 shares of common stock through a pro rata distribution from Ki Partners LLC.